Last updated: 2026-10-16 10:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Immunome, Inc. (IMNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.46, with a market capitalization of $2.03B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.64 to $30.06. This page covers its latest market performance, valuation, price trends and company information.
$2.03B | |
$17.57 | |
$63.78 | |
$2.09 | |
$17.40 | |
-- | |
1.21M | |
-- | |
$30.06 | |
$14.64 | |
-- | |
-- |
Immunome, Inc. (IMNM) is trading at $17.46 in pre-market trading as of 2026-10-16 08:02:00, up 0.32% ($0.05) from the previous close of $17.40
Pre-market trading shows how investors are pricing IMNM before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Immunome, Inc. (IMNM) moved from $19.10 to $17.46, representing a decline of 8.59% ($1.64).
The stock traded between $17.08 and $19.73 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.44 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 18.3%
IMNM is currently trading at $17.46, placing it 18.3% of the way from its 52-week low of $14.64 to its 52-week high of $30.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 177 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunome, Inc. (IMNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.